Bank Julius Baer & Co. Ltd Zurich Has $107,000 Position in Doximity, Inc. $DOCS

Bank Julius Baer & Co. Ltd Zurich cut its position in Doximity, Inc. (NYSE:DOCS) by 93.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,415 shares of the company’s stock after selling 37,259 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Doximity were worth $107,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of DOCS. Root Financial Partners LLC acquired a new position in Doximity in the 3rd quarter valued at $30,000. Whittier Trust Co. of Nevada Inc. increased its position in Doximity by 59.5% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 480 shares of the company’s stock worth $35,000 after buying an additional 179 shares during the period. Toth Financial Advisory Corp increased its position in Doximity by 100.0% in the 4th quarter. Toth Financial Advisory Corp now owns 1,000 shares of the company’s stock worth $44,000 after buying an additional 500 shares during the period. Atlantic Union Bankshares Corp increased its position in Doximity by 136.9% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 616 shares of the company’s stock worth $45,000 after buying an additional 356 shares during the period. Finally, Farther Finance Advisors LLC increased its position in Doximity by 35.7% in the 4th quarter. Farther Finance Advisors LLC now owns 1,539 shares of the company’s stock worth $68,000 after buying an additional 405 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
• Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
• Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
• Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

Doximity Trading Down 0.2%

Shares of DOCS stock opened at $18.93 on Monday. The company has a fifty day moving average of $23.94. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 1.36 and a beta of 1.36. Doximity, Inc. has a one year low of $17.15 and a one year high of $76.51.

Doximity declared that its Board of Directors has initiated a stock buyback plan on Thursday, February 5th that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to buy up to 8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Doximity

In related news, Director Kira Scherer Wampler sold 9,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total value of $234,540.00. Following the sale, the director owned 19,839 shares of the company’s stock, valued at $517,004.34. The trade was a 31.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.77, for a total value of $59,502.93. Following the completion of the sale, the insider directly owned 89,396 shares in the company, valued at approximately $2,303,734.92. This represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DOCS shares. Robert W. Baird reaffirmed a “neutral” rating and issued a $18.00 price target (down from $40.00) on shares of Doximity in a research report on Thursday. The Goldman Sachs Group dropped their price target on Doximity from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Thursday. Barclays reaffirmed an “equal weight” rating and issued a $20.00 price target (down from $38.00) on shares of Doximity in a research report on Thursday. JPMorgan Chase & Co. dropped their price target on Doximity from $33.00 to $28.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, KeyCorp downgraded Doximity from an “overweight” rating to a “sector weight” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $30.62.

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.